GH & Insulin Panel
Monitors the metabolic effects of exogenous growth hormone and insulin use. GH causes insulin resistance and can elevate blood sugar, while insulin carries hypoglycaemia risk. This panel tracks both efficacy and safety.
When to Test
Fasted, morning draw. For IGF-1 assessment, test after 4-6 weeks of stable GH dosing.
Testing Frequency
Every 3 months while running GH. Monthly if combining GH with insulin.
Markers in This Panel(8)
IGF-1
HormonesThe primary marker for GH activity. Confirms your GH is working and guides dosing.
Ref: 11 – 31 nmol/L
Glucose
Glucose MetabolismGH raises fasting glucose; insulin lowers it. Critical safety marker.
Ref: 3.5 – 6 mmol/L
HbA1c
Glucose Metabolism3-month glucose average; catches developing insulin resistance early.
Ref: 4 – 6 %
Insulin
Glucose MetabolismFasting insulin reveals insulin resistance from GH or exogenous insulin effects.
Ref: 2 – 25 mIU/L
Free T3
ThyroidGH increases T4-to-T3 conversion initially, then can suppress thyroid over time.
Ref: 3.5 – 6.5 pmol/L
TSH
ThyroidGH can suppress TSH; monitor thyroid function on long GH runs.
Ref: 0.4 – 4 mIU/L
Growth Hormone
HormonesSerum GH level; useful to verify exogenous GH is bioactive.
Ref: 0 – 7 mIU/L
CRP
InflammationGH has anti-inflammatory effects; CRP should decrease on GH.
Ref: 0 – 5 mg/L
Track these markers with VitalMetrics
Upload your blood test results, get AI analysis with PED context, and see how your markers trend over time.
Create Free Account